GleamWall
中文EN

URGN UroGen Pharma Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1668243 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY159.3%
TTM net income YoY60.1%
TTM EPS YoY—
Revenue 3-yr CAGR47.9%
Net income 3-yr CAGR—

Margins

Gross margin91.4%
Operating margin-12.4%
Net margin-26.3%
FCF margin-52.8%
EBITDA margin-12.2%

Returns

ROE—
ROA-28.8%
ROIC (approx.)—
Asset turnover1.10x

Leverage & solvency

Liabilities / assets146.1%
Debt / equity—
Current ratio3.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.01x
Accruals ratio28.9%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$109.79M$90.40M
Cost of revenue$12.45M$8.88M
Gross profit$97.34M$81.52M
R&D expense$67.11M$57.15M
SG&A expense$155.10M$121.15M
Operating income-$124.86M-$96.78M
Pretax income-$153.42M-$124.04M
Income tax$78,000$2.83M
Net income-$153.49M-$126.87M
EBITDA-$124.56M-$96.45M
EPS (basic)-3.19-2.96
EPS (diluted)——
Balance sheet
Cash & equivalents$110.75M$171.99M
Short-term investments$9.71M$110.67M
Receivables$33.08M$20.30M
Inventory$16.46M$9.23M
Current assets$186.02M$276.13M
PP&E, net$637,000$655,000
Total assets$200.46M$285.71M
Current liabilities$46.42M$45.95M
Long-term debt$122.21M$121.73M
Total debt$122.21M$121.73M
Total liabilities$305.93M$294.51M
Shareholders' equity-$105.47M-$8.80M
Net debt$11.46M-$50.25M
Shares outstanding48.35M42.23M
Cash flow statement
Operating cash flow-$162.44M-$96.77M
Capital expenditure$289,000$295,000
Free cash flow-$162.73M-$97.06M
Investing cash flow$61.56M-$20.61M
Financing cash flow$39.92M$194.62M
Depreciation & amortization$307,000$329,000
Stock-based compensation$11.96M$13.11M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.